1. Home
  2. VS vs XCUR Comparison

VS vs XCUR Comparison

Compare VS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

N/A

Current Price

$0.74

Market Cap

7.9M

Sector

Technology

ML Signal

N/A

Logo Exicure Inc.

XCUR

Exicure Inc.

N/A

Current Price

$1.08

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VS
XCUR
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
9.2M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
VS
XCUR
Price
$0.74
$1.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.3K
★ 75.2K
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
75.97
★ 83.37
EPS
★ N/A
N/A
Revenue
★ $2,183,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$44.02
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3711.30
N/A
52 Week Low
$0.70
$0.78
52 Week High
$1.86
$9.48

Technical Indicators

Market Signals
Indicator
VS
XCUR
Relative Strength Index (RSI) 31.82 51.47
Support Level N/A $0.96
Resistance Level $1.18 $1.52
Average True Range (ATR) 0.08 0.12
MACD -0.01 0.02
Stochastic Oscillator 15.14 73.40

Price Performance

Historical Comparison
VS
XCUR

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: